Om

Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions. Its product portfolio includes Proclarix, a blood-based diagnostic test used in prostate cancer assessment, and Entadfi, an oral therapy for benign prostatic hyperplasia. Onconetix also works on expanding its oncology diagnostics and treatment offerings through research, development, and commercialization activities across key international markets, including the United States and Europe. Headquartered in Cincinnati, Ohio, Onconetix Inc. operates at the intersection of diagnostic testing and therapeutic care, serving healthcare providers and patients in specialized cancer and men’s health settings.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ONCONETIX MED ENDAVU: Køb Onconetix ($ONCO) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Onconetix, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.